Aligos therapeutics presents positive clinical data at escmid 2024 from the alg-097558 phase 1 study

Data demonstrates a 7-day treatment regimen with the pan-coronavirus protease inhibitor alg-097558 was well tolerated and does not require ritonavir boosting
ALGS Ratings Summary
ALGS Quant Ranking